C4 Therapeutics Inc. (CCCC)
NASDAQ (NGS) NASDAQ (NGS) Primary 
C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact
C4 Therapeutics delivered strong 4Q25 results, with revenue up 111.5% YoY and operating expenses tightly controlled. CCCC's lead asset, cemsidomide, advanced into a Phase 2 registrational trial for relapsed/refractory multiple myeloma, targeting a large, growing TAM. Cash position strengthened to $297.1M, extending operational runway through 2028 and supporting continued pipeline investment.
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors
Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance. SiTime Corp. was also a top contributor. The company provides silicon timing chips for a wide range of electronics. The greatest detractor from Fund performance for the quarter was Monday.com Ltd.
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to a loss of $0.35 per share a year ago.
Brookstone Capital Management Purchases Shares of 29,325 C4 Therapeutics, Inc. $CCCC
Brookstone Capital Management purchased a new stake in shares of C4 Therapeutics, Inc. (NASDAQ: CCCC) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 29,325 shares of the company's stock, valued at approximately $42,000. A number of other institutional investors and hedge funds
C4 Therapeutics, Inc. - Special Call
C4 Therapeutics, Inc. - Special Call Company Participants Courtney Solberg - Senior Manager of Investor Relations Andrew Hirsch - CEO, President & Director Leonard M. J. Reyno - Chief Medical Officer Kendra Adams - CFO & Treasurer Conference Call Participants Sudan Loganathan - Stephens Inc., Research Division Binod Dhakal Bradley Canino - Guggenheim Securities, LLC, Research Division Etzer Darout - Barclays Bank PLC, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Yifan Xu - Jefferies LLC, Research Division Presentation Operator Good day, and welcome to the C4 Therapeutics' Phase I trial data of cemsidomide in multiple myeloma presented at IMS 2025 Conference Call.
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.26 per share a year ago.
C4 Therapeutics: An Entry Point If There's Ever Going To Be One
CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Lead candidate cemsidomide shows encouraging early efficacy and tolerability in heavily pretreated multiple myeloma patients, with key data readouts expected in Q3 2025. Cost controls and restructuring have extended CCCC's cash runway into 2027, reducing dilution risk and supporting ongoing development and partnerships.
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.41 per share a year ago.
C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
C4 Therapeutics (CCCC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.68 per share a year ago.
